SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-243453
Filing Date
2019-09-12
Accepted
2019-09-12 08:34:09
Documents
14
Period of Report
2019-09-11
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d801818d8k.htm   iXBRL 8-K 32502
2 EX-99.1 d801818dex991.htm EX-99.1 14857
6 GRAPHIC g801818g0912093308189.jpg GRAPHIC 2579
  Complete submission text file 0001193125-19-243453.txt   181020

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA apls-20190911.xsd EX-101.SCH 3066
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20190911_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20190911_pre.xml EX-101.PRE 11405
8 EXTRACTED XBRL INSTANCE DOCUMENT d801818d8k_htm.xml XML 3333
Mailing Address 6400 WESTWIND WAY SUITE A CRESTWOOD KY 40014
Business Address 6400 WESTWIND WAY SUITE A CRESTWOOD KY 40014 502-241-4114
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 191089562
SIC: 2834 Pharmaceutical Preparations